

CLAIMS

1. A compound capable of acting as a cationic lipid, the compound comprising a cholesterol group having linked thereto a head group; and wherein the head group is more positive than the head group of DC-Chol; but wherein the compound is not synthesised by reacting spermidine and cholesterol chloroformate in CH₂Cl₂ in the presence of *N,N*-diisopropylaminopropylamine.

2. A compound according to claim 1 wherein the cholesterol group is cholesterol.

3. A compound according to claim 1 or claim 2 wherein the cholesterol group is linked to the head group via a carbamoyl linkage.

4. A compound according to any one of claims 1 to 3 wherein the head group is a polyamine group.

5. A compound according to claim 4 wherein the polyamine group is a naturally occurring polyamine.

6. A compound according to claim 5 wherein the polyamine is any one of spermidine, spermine or caldopentamine.

7. A compound according to any one of claims 1 to 6 in admixture with or associated with a nucleotide sequence.

8. A process of preparing a compound according to any one of claims 1 to 7 comprising reacting a cholesterol group with a head group.

9. A process according to claim 8 wherein the process comprises at least one step utilising aza-Wittig methodology.

10. A compound according to any one of claims 1 to 7 or a compound when prepared by the process of claim 8 or claim 9 for use in therapy.

5 11. Use of a compound according to any one of claims 1 to 7 or a compound when prepared by the process of claim 8 or claim 9 in the manufacture of a medicament for the treatment of genetic disorder or condition or disease.

10 12. A cationic liposome formed from the compound according to any one of claims 1 to 7 or a compound when prepared by the process of claim 8 or claim 9.

15 13. A method of preparing a cationic liposome comprising forming the cationic liposome from the compound according to any one of claims 1 to 7 or a compound when prepared by the process of claim 8 or claim 9.

20 14. A cationic liposome according to claim 12 or a cationic liposome as prepared by the method of claim 13 for use in therapy.

25 15. Use of a cationic liposome according to claim 12 or a cationic liposome as prepared by the method of claim 13 in the manufacture of a medicament for the treatment of genetic disorder or condition or disease.

16. A combination of a nucleotide sequence and any one or more of: a compound according to any one of claims 1 to 7, a compound when prepared by the process of claim 8 or claim 9, a cationic liposome according to claim 12, or a cationic liposome as prepared by the method of claim 13.

25 17. A combination according to claim 16 for use in therapy.

30 18. Use of a combination according to claim 17 in the manufacture of a medicament for the treatment of genetic disorder or condition or disease.

19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 or a compound when prepared by the process of claim 8 or claim 9 admixed with a pharmaceutical and, optionally, admixed with a pharmaceutically acceptable diluent, carrier or excipient.

5

20. A pharmaceutical composition comprising a cationic liposome according to claim 12 or a cationic liposome as prepared by the method of claim 13 admixed with a pharmaceutical and, optionally, admixed with a pharmaceutically acceptable diluent, carrier or excipient.

10

21. A compound or a cationic liposome substantially as described herein and with reference to any one of the Figures.

15 22. A process substantially as described herein and with reference to any one of the Figures.